Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | TKT | P29401 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | INMT | O95050 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749731 | 0.70 | KMT2A (0.47) | CHRNB2CHRNA4CHRNA1CHRNA7NPC1 | |
| SCHEMBL6640697 | 0.70 | TLR8 (0.46) | CYP11B1CYP11B2 | |
| SCHEMBL7123376 | 0.69 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA1CHRNA7NPC1 | |
| SCHEMBL30419289 | 0.68 | SIGMAR1 (0.47) | CYP11B1CYP11B2MAPT | |
| SCHEMBL4289948 | 0.65 | TKT (0.44) | CHRNB2CHRNA4TKTCYP11B1CYP11B2 | |
| SCHEMBL4410512 | 0.65 | NOS1 (0.42) | TKTCYP11B1CYP11B2 | |
| SCHEMBL9917318 | 0.64 | NOS1 (0.39) | TKTCYP11B1CYP11B2 | |
| SCHEMBL6630716 | 0.63 | TKT (0.54) | TKTCYP11B1CYP11B2 | |
| SCHEMBL27955068 | 0.63 | NOS1 (0.41) | TKTCYP11B1CYP11B2 | |
| SCHEMBL7504394 | 0.63 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA1CHRNA7NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | claimed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | CHRNA7, CHRNA2, CHRNA1 | CHRNB2 4/4885CHRNA4 11/4885CHRNA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.